Advancing Knowledge,
Improving Patient Outcomes

AcademicCME is a jointly accredited healthcare solutions medical education company designed to impact practice behavior by providing clinicians with multi-format educational resources in various therapeutic areas. Our mission is to improve patient outcomes through practical, customized and comprehensive continuing education.

CE Courses

Accurate Diagnosis and Guideline-Driven Individualized Treatment Plans to Manage Patients with Non-Tuberculous Mycobacterial Lung Disease

This program is derived from a lecture administered at the 2023 Eastern Pulmonary Conference. The expert faculty, Drs. Reynold A. Panettieri, Jr. and Anne E. O’Donnell…

Improving Systematic Monitoring for Glucocorticoid Adverse Events to Guide Appropriate Use of Steroid-Sparing Therapy in Patients with gMG

Myasthenia gravis is one of the oldest recognized autoimmune neurologic diseases, but practice-changing clinical trials remain challenging despite greater knowledge of pathophysiology…

Advances in Disease Management of Generalized Myasthenia Gravis

This CME program will highlight recent advances in disease management of generalized myasthenia gravis (MG)…

Clinical Update on Anemia of Chronic Kidney Disease: Improving Outcomes for All Patients

Anemia is a common complication in CKD (aCKD) and is associated with a reduced quality of life and increased morbidity and mortality…

Optimizing Echocardiographic and CMR Assessment in the Diagnosis and Management of Hypertrophic Cardiomyopathy

This CME program, derived from content presented at the European Association of Cardiovascular Imaging Annual Congress EACVI 2023 in Barcelona, Spain, will highlight how to optimize echocardiographic and CMR assessment in the diagnosis and management of hypertrophic cardiomyopathy…

Case-Based Learning on Optimal Immuno-Oncologic Management of Extensive-Stage Small Cell Lung Cancer

Small-cell lung cancer is a particularly deadly subtype of lung cancer, which accounts for approximately 15% of new lung cancer diagnoses. Unfortunately, nearly 60% of patients with SCLC present first with metastatic or extensive-stage (ES) disease, for whom standard of care therapy for nearly 40 years has been platinum doublet chemotherapy (cisplatin or carboplatin combined with etoposide or irinotecan), with or without prophylactic cranial irradiation…

Upcoming Events

10th European Stroke Organisation Conference – ESOC 2024

May 15th – 17th, 2024

Texas Neurological Society Summer Meeting

July 19th – 20th, 2024

ESMO Congress 2024

September 13th – 17th, 2024

Alliance Industry Summit 2024

September 16th – 18th, 2024

Leave a Reply

Your email address will not be published. Required fields are marked *